obgyn oncology
Risk of Malignancy Index (RMI) for Ovarian Mass
Predicts ovarian malignancy probability from USS features, menopausal status, and CA-125. RMI >= 200 warrants specialist referral.
Score interpretation
Low risk (RMI < 25)
→ Manage in general gynaecology; repeat USS in 3-4 months
Moderate risk (RMI 25-200)
→ Gynaecology-oncology review; MDT discussion
High risk (RMI >= 200)
→ Gynaecological oncology centre referral; staging CT; specialist surgery
Interpretation bands for the RMI Ovarian. Apply clinical judgement and local guidance.
References
Related
Curated clinical cross-links plus same-class fallbacks.
Drugs
- Zoledronic Acid · Bisphosphonate (IV)
- Denosumab · RANK Ligand Inhibitor (Anti-resorptive)
- Cetuximab · Anti-EGFR Monoclonal Antibody — Head and Neck Cancer
- Cisplatin · Platinum Chemotherapy — Head and Neck Cancer
- Zoledronic Acid · IV Bisphosphonate
- Dexamethasone (Antenatal / OHSS / CAH) · Corticosteroid — Obstetric and Gynaecological
Decision support only — verify against a current formulary, NICE, or your local guideline before clinical use.